GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Debt
Debt-to-Equity RatioN/A
Current Ratio28.32
Quick Ratio28.32
Price-To-Earnings
Trailing P/E Ratio-13.18
Forward P/E Ratio-12.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$20,000.00
Price / Sales31,641.25
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book4.27
Profitability
EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-25.35%
Return on Assets-24.04%
Miscellaneous
Employees40
Outstanding Shares42,500,000
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.05. View GlycoMimetics' Earnings History.
What price target have analysts set for GLYC?
5 Wall Street analysts have issued 12 month price objectives for GlycoMimetics' shares. Their predictions range from $21.00 to $35.00. On average, they expect GlycoMimetics' stock price to reach $28.25 in the next twelve months. View Analyst Ratings for GlycoMimetics.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include OPKO Health (OPK), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Xencor (XNCR), TESARO (TSRO), Akcea Therapeutics (AKCA), Global Blood Therapeutics (GBT), Insmed (INSM), ACADIA Pharmaceuticals (ACAD) and Spectrum Pharmaceuticals (SPPI).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Mrs. Rachel K. King, CEO & Director (Age 59)
- Mr. Brian M. Hahn, CFO & Sec. (Age 44)
- Dr. John L. Magnani Ph.D., Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
- Dr. Helen M. Thackray M.D., FAAP, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
- Mr. Henry Flanner, VP of Technical Operations
Has GlycoMimetics been receiving favorable news coverage?
News headlines about GLYC stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlycoMimetics earned a coverage optimism score of 0.24 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (5.89%), Redmile Group LLC (5.37%), Franklin Resources Inc. (4.96%), BlackRock Inc. (2.79%), Columbus Circle Investors (1.32%) and Artal Group S.A. (0.76%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Daniel M Junius, Helen M Thackray and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which institutional investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Barclays PLC. Company insiders that have sold GlycoMimetics company stock in the last year include Brian M Hahn, Helen M Thackray and M James Barrett. View Insider Buying and Selling for GlycoMimetics.
Which institutional investors are buying GlycoMimetics stock?
GLYC stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Redmile Group LLC, Columbus Circle Investors, Farallon Capital Management LLC, Millennium Management LLC, BlackRock Inc., Franklin Resources Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $14.89.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $672.30 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
